


2025 MIPS Seminar Program

 17 Mar 2025  12:00 pm to 1:00 pm  LT3

SUBCUTANEOUS DRUG DELIVERY: SO WHAT'S THE BIG DEAL?

Dr David Kang



David Kang is Director of Drug Delivery and Innovation at Halozyme Therapeutics. He has been with Halozyme since 2008 and is a subject matter expert in recombinant human hyaluronidase facilitated rapid, large volume subcutaneous administration of biotherapeutics.

He is also an officer of the Subcutaneous Drug Development and Delivery Consortium, and is a member of the Industry Council of the Controlled Release Society.

Prior to Halozyme, David spent over a decade between Pfizer and Schering-Plough researching oncology therapeutics and viral based gene delivery.

He started his research career at the University of California at San Diego working on gene therapy approaches on infectious disease, where he also did his undergraduate studies in microbiology and graduate work in virology.